Therefore, agents that inhibit VEGF/VEGFR signaling may be useful in reducing intestinal inflammation in patients with IBD, and Saccharomyces boulardii was found to block angiogenesis of VEGFR signaling and regulate the acute and chronic inflammation of the intestinal mucosa associated with the progression of IBD [13]. Here, VEGFA is linked to irritable bowel syndrome.